Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma.J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.

Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics. 2013 Sep-Oct;33(5):1323-41. doi: 10.1148/rg.335125214.

Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update.Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.

Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47(1):207-214.

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60.

Dr. Josep Llovet

Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

<p>Measures treatment response, specifically to cytotoxic drugs, based on tumor shrinkage.</p>

<p>Measures treatment response by HCC tumor size.</p>

mRECIST

The mRECIST Criteria Measures treatment response, specifically to cytotoxic drugs, based on tumor shrinkage.

Length

BCLC Staging Classification

Metroticket Calculator

REACH-B Score

EB Medicine is the premier provider of evidence-based clinical content and CME resources for emergency medicine practitioners.

Listen to the VACO co-creators break down how to use VACO\, what it does\, and what it doesn’t.

Calc Function